Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

Revenues for Syngene International Limited are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 44.267765
debtToEquity 12.226000
earningsGrowth 0.144000
revenueGrowth 0.107000
grossMargins 0.681930
operatingMargins 0.114350
trailingEps 12.630000
forwardEps 16.850000

SYNGENE's low Debt-to-Equity ratio suggests the company is minimally leveraged, with limited reliance on debt to finance its operations. This reduced financial risk positions the company for greater stability and financial health, appealing to investors who value conservative financial management.
Syngene International Limited's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for Syngene International Limited.
With a forward EPS greater than its trailing EPS, SYNGENE is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

Price projections for SYNGENE have been revised down over time, reflecting a less optimistic outlook. Analysts appear to be adjusting their expectations, signaling concerns about the company's ability to sustain its previous growth levels.

Insider Transactions:

Insider Transactions for SYNGENE
Insider Transactions for SYNGENE


26 sell transactions of SYNGENE were recorded, with market price hovering near 819.1826876126803.No sell transactions were carried out during the period under review.SYNGENE has seen more buys than sells at its current price levels, which may suggest optimism among investors. This buying trend could indicate that the market expects a favorable performance for the stock in the near future.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


Recent analysis shows a strong buy bias for SYNGENE, encouraging investors to view it as a solid investment option. The positive sentiment surrounding SYNGENE suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.